ATS Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATSAF research report →
Price Chart
About the company
ATS Corporation, operating globally through its subsidiaries, delivers comprehensive automation solutions. The company's expertise spans the entire lifecycle of automated manufacturing and assembly systems, encompassing planning, design, construction, commissioning, and ongoing servicing, which also includes providing specialized automation products and test solutions. Their enterprise-level services involve meticulous project management, strategic selection and coordination of partners and suppliers, facility layout and operational design, and robust business case development and project justification.
- CEO
- Andrew P. Hider
- IPO
- 2009
- Employees
- 6,000
- HQ
- Cambridge, ON, CA
Get TickerSpark's AI analysis on ATSAF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.06B
- P/E
- 245.89
- PEG
- 1.39
- P/S
- 0.79
- P/B
- 1.33
- EV/EBITDA
- 11.26
- Div Yield
- 0.00%
- Gross Margin
- 27.12%
- Op Margin
- 5.70%
- Net Margin
- 0.30%
- ROE
- 0.48%
- ROIC
- 2.05%
Latest fiscal year · YoY change
- Revenue
- $2.58B+18.1%
- Gross Profit
- $725.81M+18.5%
- Op Income
- $222.49M
- Net Income
- $127.43M+4.4%
- EPS
- $1.39+5.3%
- OCF Growth
- -40.9%
- FCF Growth
- -70.8%
- 52W High
- $45.80
- 52W Low
- $25.66
- 50D MA
- $41.93
- 200D MA
- $36.52
- Beta
- 1.63
- RSI (14)
- 62
- Avg Volume
- 44.93K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ATS posted strong Q2 order growth and record life sciences backlog, but tariff-related packaging delays and softer mix led management to trim full-year revenue and margin expectations.· November 4, 2026
- Q2 orders were $827 million, up 12.7% year over year, and backlog ended near $2 billion with life sciences backlog at a record $1.2 billion.
- Q2 revenue was $666 million, adjusted earnings from operations were $57.4 million, adjusted margin was 8.6% vs. 10.9% last year, and adjusted EPS was $0.27.
- Gross margin was 28.6%, down 131 basis points year over year, driven by mix and absorption; operating cash flow was $81 million vs. $28 million last year.
- Management said full-year modest revenue growth and margin expansion are no longer expected because of packaging-order delays and the time needed to convert backlog to revenue.
- The fixed cost transformation program is targeting $65 million to $75 million of net annualized savings, with implementation over the next 15 months and benefits building progressively.
Q2 revenue was $666 million, in line with guidance. Order bookings were $827 million, up 12.7% year over year, and trailing 12-month book-to-bill was 1.05x. Adjusted earnings from operations were $57.4 million, adjusted margin was 8.6% versus 10.9% a year ago, gross margin was 28.6% (down 131 bps year over year), and adjusted EPS was $0.27. Backlog ended at approximately $2 billion, including $1.2 billion in life sciences. Looking ahead, management expects Q3 revenue of $640 million to $680 million and said it no longer expects to achieve prior goals for modest revenue growth or margin expansion in fiscal 27. CapEx and intangible investment for fiscal 27 is expected to be $60 million to $80 million.
Douglas Wright emphasized that end-market demand remains healthy, led by life sciences and nuclear, and said the company’s highest life sciences backlog ever reflects a more diversified pipeline across radiopharma, medical device, diabetes, vision care, sterilization, and liquid pharma inspection. He framed the tariff-related packaging delay as temporary and said the recent U.S. tariff modifications should help customers resume capital spending over time. His tone was constructive and confident, with repeated emphasis that ATS is positioning capital and resources toward higher-return growth areas.
Anne Cybulski said the quarter showed meaningful progress in bookings and backlog, but near-term margins are being pressured by lower revenues and mix while the fixed cost transformation program ramps. She quantified the program at $65 million to $75 million of net annualized savings, or roughly 250 basis points of margin expansion, and said it should build over the next 15 months as facilities are closed and the footprint is reduced by about 10%. She also noted Q2 operating cash flow of $81 million, working capital at 13.4% of revenue, net debt to adjusted EBITDA of 3.1x, and fiscal 27 CapEx/intangible spend expected at $60 million to $80 million.
Analysts focused on the tariff-driven packaging delays, the longer conversion cycle in life sciences, and whether bookings strength would translate into revenue growth sooner. Management said the tariff impact was concentrated in packaging systems sold from Canada into the U.S., while life sciences strength was broad-based and led by radiopharma with repeat business in other modalities. On the fixed cost program, management said savings are net of planned reinvestment and will build progressively, while also saying the backlog is strong enough to support better medium-term revenue but that some projects are inherently long-cycle.
The bull case from this call is that ATS is seeing strong demand in attractive end markets, especially life sciences and nuclear, with record backlog in life sciences and a healthy 1.05x trailing book-to-bill. Management also pointed to expanding aftermarket revenue, a diversified pipeline, and a fixed cost program that should create structural margin improvement over time.
The main risks discussed were delayed order timing in packaging automation due to tariff uncertainty, lower near-term revenue conversion from longer-cycle projects, and margin pressure from mix and absorption. Management also said it no longer expects fiscal 27 to deliver the previously planned modest revenue growth and margin expansion, and noted leverage will remain moderately above target absent acquisitions or portfolio actions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.5%
- Shares Outstanding
- 91.78M
- Float Shares
- 72.93M
Our ATSAF coverage
Recent articles, reports, and earnings notes.
No research on ATSAF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATSAF report →ATS to Participate in the Scotiabank Transportation & Industrials Conference
businesswire.com · Nov 11
ATS to Participate in the Baird 2026 Global Industrial Conference
businesswire.com · Nov 9
Avalanche to support NYSE's affiliated upcoming digital ATS: NYSE Content Update
prnewswire.com · Nov 9
G Q3 Earnings Beat Estimates on ATS Growth, Margins Expand
zacks.com · Nov 6
What ATS (ATS) Said on Its Q2 Earnings Call
marketbeat.com · Nov 5
ATS (ATS) Misses Q2 Earnings and Revenue Estimates
zacks.com · Nov 4
ATS Reports Second Quarter Fiscal 2027 Results
businesswire.com · Nov 4
Implied Volatility Surging for ATS Corporation Stock Options
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.